Telomerase activity and apoptosis genes as parameters of lymphocyte aging in Down syndrome patients  by Abdel-Salam, Ekram et al.
The Egyptian Journal of Medical Human Genetics (2013) 14, 171–176Ain Shams University
The Egyptian Journal of Medical Human Genetics
www.ejmhg.eg.net
www.sciencedirect.comORIGINAL ARTICLETelomerase activity and apoptosis genes as parameters
of lymphocyte aging in Down syndrome patientsEkram Abdel-Salam a,*, Iman Abdel-Meguid a, Soheir Korraa ba Department of Pediatrics, Genetics Unit, Faculty of Medicine – Cairo University, Egypt
b Department of Radiation Health, National Center for Radiation Research and Technology, EgyptReceived 3 December 2012; accepted 1 January 2013










FasL and telomeraseCorresponding author. Tel.:
mail address: ekab@link.net
er review under responsibilit
Production an






g.2013.0Abstract It is hypothesized that Down syndrome (DS) patients are associated with abnormalities
of the immune system. Accordingly, this study was conducted to measure replicative aging and
apoptosis in lymphocytes, which play an important role in the immune system, before and after
being biostimulated with He:Ne laser. Replicative aging was measured in terms of telomerase activ-
ity, and ETS-2 gene relative expression. Apoptosis was measured in terms of DNA fragmentation
and apoptosis genes (Fas, FasL and Bax) and antiapoptotic Bcl-2 protein. Results showed that Tel-
omerase activity, ETS-2 mRNA expression, plasma DNA fragmentation, Fas and FasL were sig-
niﬁcantly higher among DS patients compared to controls: Telomerase activity (1.5 ± 0.5 vs.
0.9 ± 0.4, p< 0.001); ETS2 mRNA expression (0.6 ± 0.1 vs. 0.43 ± 0.04, p< 0.0001); plasma
DNA fragmentation (0.45%± 0.12 vs. 0.2%± 0.1, p< 0.0001); Fas protein (5.3 ± 1.2 vs.
2.3 ± 0.2, p< 0.0001); FasL mRNA relative expression (0.37 ± 0.05 vs. 0.24 ± 0.01,
p< 0.001); Bax mRNA relative expression (0.9 ± 0.1 vs. 0.5 ± 0.1, p< 0.00001). Bcl-2 protein
was signiﬁcantly low in DS patients compared to controls (8.6 ± 1.3 vs. 10 ± 2.1, p< 0.01). He:Ne
laser biostimulation applied to evaluate lymphocytes’ response signiﬁcantly increased the former
parameters in DS patients compared to their level before irradiation, except for Bcl-2, which was
signiﬁcantly decreased. In conclusion: increased telomerase activity associated with increased activ-
ity and overexpression of ETS-2 on chromosome 21 in DS patients may contribute to the increased
rate of early senescence in circulating lymphocytes, which consequently contributes to the abnor-
malities of the immune system observed in DS. Increased apoptosis is due to increased oxidative
stress, which induces an increase in the apoptotic genes Bax, Fas and FasL accompanied by a
decrease in the antiapoptotic gene Bcl-2.
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1.0011. Introduction
Down syndrome (DS), or trisomy 21, is the most frequent ge-
netic cause of mental retardation in man; the incidence is
approximately one in 750 live births [1]. Autoimmune phenom-
ena manifested by the increased frequency of hematologicalier B.V. All rights reserved.
172 E. Abdel-Salam et al.malignancies, autoimmune diseases and infections in DS, had
already led to the hypothesis that DS is associated with abnor-
malities of the immune system [2–6].
Immunosenescence is the global term used to describe the
observed age-associated decline in immune competence char-
acterized by functional and phenotypic alterations to the im-
mune system as a whole [7]. Immunosenescence in the elderly
human population is associated with increased susceptibility
to infectious diseases and cancer, reduced effectiveness of vac-
cinations, increased autoimmunity, and damage to various or-
gan systems through dysregulated inﬂammation [8–12].
Cellular senescence is deﬁned as the irreversible loss of divi-
sion potential in somatic cells and is marked by a number of
distinct phenotypic changes [13]. It is believed that senescence
has an important role in vivo, protecting organisms on one
hand against a build-up of cells containing DNA damage
and on the other hand contributing to age-dependent tissue
dysfunction [13]. Evidence is mounting that cells bearing senes-
cent markers accumulate in several tissues with age [14,15], as
well as in several age-related diseases [16].
At least a few hundred nucleotides of telomere repeats must
‘‘cap’’ each chromosome end in order to suppress DNA damage
pathways. Critically short or ‘‘uncapped’’ telomeres may be re-
paired by the enzyme telomerase or by recombination [17].
However, the capacity of these telomere repair processes ap-
pears limited inmost human somatic cells [18]. Apoptosis or cel-
lular senescence is triggered when too many ‘‘uncapped’’
telomeres accumulate [19], not only posing a barrier to tumor
growth, but also contributing to loss of cells with age [20]. How-
ever, human T lymphocytes are able to upregulate telomerase in
concert with activation and thereby retarding telomere loss [21].
Cytogenetic and molecular studies of individuals with par-
tial duplications of chromosome 21 and features of DS have
sought a ‘‘critical region’’ on this chromosome, whose duplica-
tion is postulated to be both necessary and sufﬁcient to pro-
duce the DS phenotype [22]. Located on the critical region is
the transcription factor Erythroblastosis virus oncogene
homolog 2 (ETS-2), which is a pro-oncogene, located in hu-
man chromosomal region 21q22.3 [23]. ETS-2 may be involved
in the regulation of cellular proliferation and differentiation
and may play a critical role in T-cell activation and cytokine
production [24]. However, increased levels of ETS-2 have been
shown to predispose to apoptosis [25]. An in vitro study indi-
cated that ETS-2 promotes degeneration of DS neurons by
activation of a mitochondrial pathway [26].
The apoptosis cascade can be triggered by 2 main pathways,
via an intrinsic, endogenous system such as the mitochondrial
Bax/Bcl-2 or via an extrinsic system involving transmembrane
receptors of the Fas and FasL [27]. FasL is a 40-kDa type II
membrane protein that belongs to the tumor necrosis factor
superfamily and induces apoptosis through cognate interaction
with its receptor Fas (CD95/Apo-1), which includes recogni-
tion of a distinctive element on the target cell by a correspond-
ing lymphocyte receptor, formation of a contact zone between
the two cells, and induction of cytolysis [28]. Activation of the
Fas receptor through an interaction with transmembrane FasL
leads to the recruitment and activation of numerous signaling
molecules, including apoptosis-inducing transcription factors.
This mechanism is crucial for the suicide of activated T cells
and macrophages [29]. However this mechanism has not been
previously measured in blood of DS.The aim of the present study is to investigate whether lym-
phocytes in DS patients are subjected to early senescence. This
is achieved by measuring replicative aging and apoptosis. Rep-
licative aging was measured in terms of telomerase activity,
and ETS-2 mRNA gene relative expression. Apoptosis was
measured in terms of DNA fragmentation and apoptosis gene
mRNA expression (Bax and FasL and fas protein) and antiap-
optotic Bcl-2 protein. Stimulation of lymphocytes was carried
out with He:Ne laser at laser ﬂuency known to induce biosti-
mulation in blood cells [30]. Markers of aging and apoptosis




Patients were 62 Down syndrome cases (34 males and 28 fe-
males). Age ranged from 2 to 9 years (mean 4.2 ± 1 year).
Controls were 30 matched healthy normal children (18 males
and 12 females), age ranged from 2 to 9 years (mean
4.5 ± 1.1 years). DS patients were selected from cases already
diagnosed by chromosomal karyotyping in the genetics unit,
pediatric department, Cairo University. The selective criteria
of the patients and controls were to be free from any infection
and in good nutritive status. Blood was drawn after an in-
formed consent of the parents in accordance with the current
revision of the 1975 Helsinki Declaration.
Methods
Blood irradiation
Blood was distributed over 96 well tissue culture plates and
were incubated for 48 h with and without irradiation with
2 J/cm2 He:Ne laser at a wave length of 632.8 nm, which in-
duces lymphocyte division.
Telomerase assay
Telomerase activity was determined using the telomerase re-
peat ampliﬁcation protocol (TRAP). PCR ELISA protocol
was carried according to the manufacturer’s protocol (Boeh-
ringer Mannheim Biochemicals, Mannheim, Germany) [31].
Reverse transcriptase-polymerase chain reaction (RT-PCR)
analysis for ETS-2, FASL and Bax
Total RNA was extracted from lymphocytes using a QIAGEN
RNA extraction Kit (QIAGEN Inc, USA). The RNA samples
were reverse transcribed using superscript reverse transcriptase,
using a QIAGEN One Step RT-PCR kit (QIAGEN Inc USA,
Clini Lab). EST-2 primer sequences, forward: 50-GTAGTG
CAGAAAGClCCCGCAG-CGGCAGGATGAAT-30 reverse
50 GTCGGAGAAITCATGCCGAACCTCTGCAG-30, FasL
primer sequences, (forward: 50-CAA GTC CAA CTC AAG
GTC CAT GCC-30; reverse: 50-CAG AGA GAG CTC AGA
TAC GTT- TGAC-30). Primers for b-actin were synthesized
simultaneously as an internal reference for all samples
(forward: 50-GTGGGGCGCCCCAGGCACCA-30; reverse:
50-CTC CTT AAT GTC ACG CAC GAT TTC-30). Bax
sequences [32], (forward: 50-CAC CAG CTC TGA- GCA
GAT G-30; reverse: 50-GCG AGG CGG TGA- GCA CTC C-
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Figure 1 ETS-2 mRNA expression in DS patients compared to
controls Lanes 1–3 before He:Ne laser and lanes 4–6 post HeNe
laser.
Telomerase activity and apoptosis genes as parameters of lymphocyte aging in Down syndrome patients 17330). [33] 5 ll of RT reaction of each of the formed cDNA was
processed for PCR. 10 lL from each PCR reaction product
was separated on a 2% agarose gel then stained with ethidium
bromide. The appearance of speciﬁc bands (ETS-2 470 bp, Bax
516 bp, b-actin 540 and FasL 345 bp) was evaluated under
ultraviolet light and photographed.
Determination of Soluble Fas was in duplicate plasma sam-
ples. Soluble Fas protein was measured using commercially
available sandwich enzyme-linked immunosorbent assay (ELI-
SA) kits .This kit uses the competitive binding enzyme immu-
noassay format [34].
ELISA Bcl-2
The amounts of Bcl2 in circulating lymphocytes were deter-
mined by a sandwich enzyme linked immunosorbent assay
(ELISA) purchased from Clinical, using two anti-human
BCL2 monoclonal murine antibodies [35].
DNA fragmentation assay
This is done according to themethod of Ioannou andChen 1996
[36]. In apoptosis DNA is broken down into fragments ranging
from 20 to 200 base pairs. Separation of both fragmented and
total DNA was carried out using DNA separating kit. DNA
fragments were gradiently separated from the intact DNAusing
polyethylene glycol (5% in Ethyl ether) and then quantiﬁed
spectrophotometrically using Hoechst 33258 (0.2 lg/ml) as a
chromophore.
Statistical analysis
Each experimental condition was performed in triplicate. Data
are expressed as mean ± SD. Comparisons were made by
Student’s t-test.
Results
Markers of cell proliferation in DS patients are presented in
Table 1. Telomerase activity was signiﬁcantly higher among
DS patients compared to controls (1.5 ± 0.5 vs. 0.9 ± 0.4,
p< 0.001). He: Ne laser irradiation signiﬁcantly increased tel-
omerase activity among DS patients compared to their levels
before irradiation (20.4 ± 2 vs. 1.5 ± 0.5 p< 0.00001) and
compared to controls post irradiation (20.4 ± 2 vs. 16.5 ± 4,
p< 0.001). ETS-2 mRNA expression (Fig. 1) was signiﬁcantly
increased in DS patients compared to controls (0.6 ± 0.1 vs.
0.43 ± 0.04, p< 0.0001). Exposure to He:Ne laser induced a
signiﬁcant increase in ETS-2 mRNA expression in DS patients
compared to itself before laser irradiation (0.8 ± 0.1 vs.
0.6 ± 0.1, p< 0.01) and compared to controls after irradia-
tion (0.8 ± 0.1 vs. 0.5 ± 0.03, p< 0.001).Table 1 Markers of cell proliferation and replicative aging in DS p
Before laser irradiation
DS patients Controls P*
Telomerase 1.5 ± 0.5 0.9 ± 0.4 0.001
ETS-2 0.6 ± 0.1 0.43 ± 0.04 0.0001
P*: DS vs. controls before laser.
P**: DS before laser vs. DS post laser.
P***: DS vs. controls post laser.Markers for apoptosis are presented in Table 2. Plasma
DNA fragmentation was signiﬁcantly higher among DS
patients compared to controls (0.45%± 0.12 vs. 0.2 ±
0.1%, p< 0.0001). Exposure to He:Ne laser induced a signif-
icant increase in DNA fragmentation in DS patients compared
to itself before laser irradiation (0.87 ± 0.5% vs. 0.45 ±
0.12%, p< 0.0001) and compared to controls (0.87 ± 0.5%
vs. 0.16 ± 0.02%, p< 0. 0001).
Fas was signiﬁcantly higher in DS patients compared to
controls (5.3 ± 1.2 vs. 2.3 ± 0.2, p < 0.0001). Exposure to
He:Ne laser induced a signiﬁcant increase in Fas among DS
patients compared to itself before laser irradiation (8.7 ± 2.8
vs. 5.3 ± 1.2, p< 0.0001) and compared to controls
(8.7 ± 2.8 vs. 4.5 ± 1.3, p< 0.001). FasL mRNA expression
(Fig. 2) in circulating lymphocytes was also signiﬁcantly higher
in DS patients compared to controls (0.37 ± 0.05 vs.
0.24 ± .04, p< 0.01) and became signiﬁcantly increased after
exposure to He:Ne laser compared to itself before laser irradi-
ation (0.6 ± 0.03 vs. 0.37 ± 0.05, p< 0.001) and compared to
controls (0.6 ± 0.03 vs. 0.13 ± 0.02, p< 0.00001).
There was a signiﬁcant increase in Bax mRNA relative con-
centration (Fig. 3) in DS patients compared to controls
(0.9 ± 0.01 vs. 0.5 ± 0.1, p< 0.00001) accompanied by a sig-
niﬁcant decrease in Bcl-2 protein in circulating lymphocytes
compared to controls (8.6 ± 1.3 vs. 10 ± 2.1, p< 0.01).
Biostimulation by He:Ne laser induced a signiﬁcant increase
in Bax mRNA relative concentration in DS patients compared
to itself before laser irradiation (1.4 ± 0.5 vs. 0.9 ± 0.1,
p< 0.00001) and compared to controls (1.4 ± 0.5 vs.
0.07 ± 0.02, p< 0.00001). This was accompanied by a signif-
icant decrease in Bcl-2 protein in circulating lymphocytes of
DS patients compared to its level before laser irradiation
(4.2 ± 0.9 vs. 8.6 ± 1.3, p< 0.0001) and compared to con-
trols (4.2 ± 0.9 vs. 11.4 ± 4, p< 0.00001).
Discussion
Results showed that telomerase activity was signiﬁcantly high-
er among DS patients compared to controls and that He:Ne
biostimulation signiﬁcantly increased its activity both in DS
patients and controls. In old men with trisomy 21 it has beenatients compared to controls.
Post laser irradiation
DS patients P** Controls P***
20.4 ± 2 0.00001 16.5 ± 4 0.001
0.8 ± 0.1 0.01 0.5 ± 0.03 0.001
Table 2 Percentage of DNA fragmentation, FasL, Fas, Bax and Bcl-2 in blood of DS patients.
Before laser irradiation Post laser irradiation
DS patients Controls P* DS Patients P** Controls P***
Percentage DNA fragmentation 0.45 ± 0.12 0.2 ±. 0.1 0.0001 0.87 ± 0.5 0.0001 0.16 ± 0.02 0.0001
Fas 5.3 ± 1.2 2.3 ± 0.2 0.0001 8.7 ± 2.8 0.0001 4.5 ± 1.3 0.001
FasL 0.37 ± 0.05 0.24 ± 0.01 0.001 0.6 ± .03 0.001 0.13 ± 0.02 0.00001
Bax 0.9 ± 0.1 0.5 ± 0.1 0.0001 1.4 ± 0.5 0.00001 0.07 ± 0.02 0.00001
Bcl-2 8.6 ± 1.3 10 ± 2.1 0.01 4.2 ± 0.9 0.0001 11.4 ± 4 0.00001
P*: DS vs. controls before laser.
P**: DS before laser vs. DS post laser.
P***: DS vs. controls post laser.
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Figure 2 FasL mRNA expression in DS patients before and
after laser exposure Lanes 1–3 before He:Ne laser and lanes 4–6
post HeNe laser.
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Figure 3 Bax mRNA expression in DS patients before and after
laser exposure Lanes 1–3 before He:Ne laser and lanes 4–6 post
He:Ne laser.
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panied by reduced telomere length [37]. This observation is re-
garded as one of the cytogenetic parameters that represents a
state of genetic instability and is suggested to play a role in
the pathomechanism of typical features of Down syndrome,
such as dementia [38]. Telomere length was found to be signif-
icantly lower in amniocytes from trisomy 21 conceptions com-
pared to the control group [39]. In the present study DS
patients, which have been previously shown to have short telo-
meres [39], had increased telomerase activity, which is consid-
ered a phenomenon opposite to normal.
A proposed mechanism for DS features is based on the im-
pact of gene dosage effect [40] due to the extra-genetic material
of the supernumerary chromosome 21. It is estimated that
approximately 500 genes could map to chromosome 21; cur-
rently, nearly 40 are known. Among them is the ETS-2 gene,
which is a transcription factor involved in embryonic develop-
ment [41] sometimes dysregulated in human cancers [42]. How-
ever, in the case of DS, an increased level of ETS-2 has been
shown to predispose to apoptosis [41,43]. Results of the pres-
ent study showed a signiﬁcant increase in ETS-2 mRNA
expression in DS patients compared to controls. This was
accompanied by a signiﬁcant increase in plasma DNA frag-
mentation, indicating that increased expression of ETS-2
mRNA induces apoptosis in DS lymphocytes. Previous studies
indicated that DS patients presented increased DNA damage
as measured by single cell gel electrophoresis assay in relation
to controls [44]. Enhanced apoptosis is a common feature intissues and organs of DS patients [45]. Thus results of the pres-
ent study indicate that apoptosis in circulating lymphocytes is
a feature in DS patients.
Fas is a type I transmembrane protein and a member of the
tumor necrosis factor receptor (TNFR) family whereas FasL is
a type II transmembrane protein and a member of TNF fam-
ily. Binding of Fas by FasL induces apoptosis of the Fas-
expressing cells [28]. In the present study plasma Fas has been
shown to be signiﬁcantly elevated in DS patients compared to
controls. It has been previously shown that neurodegeneration
in DS is associated with apoptosis due to overexpression of
Fas as measured in four different regions of cerebral cortex
and cerebellum in nine adult DS patients [46].
There was a signiﬁcant increase in mitochondrial protein
Bax mRNA relative concentration, accompanied by a signiﬁ-
cant decrease in anti-apoptotic Bcl-2 protein in circulating
lymphocytes in DS patients indicating the involvement of
mitochondria pathway in apoptosis induced in lymphocytes.
It has been previously shown that in vitro ETS-2 upregulation
in DS neurons promotes the activation of a mitochondrial-
dependent proapoptotic pathway of cell death, which is
accompanied by increased bax [40]. There was also at least
ﬁvefold elevation of Bax protein together with decreased Bcl-
2 values in four cortical regions and the cerebellum of one fetal
Down syndrome (35 weeks’ gestation) postmortem brain sam-
ple compared with a control brain sample [47].
In the present study biostimulation of leucocytes in vitro
using He:Ne laser signiﬁcantly increased DNA fragmentation
in DS patients and decreased Bcl-2 protein, while in controls
DNA fragmentation was decreased and Bcl-2 protein was sig-
niﬁcantly increased. It is believed that He:Ne laser exerts its ac-
tion by stimulating the activity of superoxide dismutase
enzyme, which has been shown, previously, to increase in the
skin of animals exposed to laser [30,48]. Exposure of DS blood
to He:Ne laser stimulates an oxidative stress, which conse-
quently increased apoptosis and its markers including Fas,
FasL, Bax and decreased antiapoptotic protein including
Bcl-2 protein.
The decrease in Bcl-2 protein can be explained by the fact
that reactive oxygen species (which are increased in DS), are
products, which have the potential to modulate critical cellular
components such as DNA, proteins and lipids, resulting in the
activation of mechanisms that lead either to cell proliferation
or to programed cell death [49].
In the present study He:Ne laser has been shown to stimu-
late the expression of ETS-2 gene. It is well known that the
ETS-2 gene family encodes a family of transcription factors in-
volved in a variety of biological processes, including growth
Telomerase activity and apoptosis genes as parameters of lymphocyte aging in Down syndrome patients 175control, transformation, T cell activation and developmental
programs [44,50–52]. However in the case of DS patients stim-
ulation of ETS-2 genes induces apoptosis [28].
It is well established that genetic condition like Down’s syn-
drome causes premature aging accompanying global senes-
cence in various organ levels and that the rate of aging for
DS patients is nearly a twofold increase as compared to
healthy subjects [53]. Aging is associated with a decline in im-
mune responses [54]. Although many aspects of the immune
system demonstrate age-associated alterations, T cells show
the greatest and most consistent changes [14,15]. Various
immunological theories and observations to explain the predis-
position of individuals with DS to infections have been pub-
lished [15] and that increased apoptosis is the main
cornerstone for this reduced infection suggesting that DS cells
may be more sensitive to proapoptotic stimuli than normal
cells [54]. Thus results of the present study provide further evi-
dence that apoptosis is a hallmark in DS patients.
In conclusion: telomerase increased activity and overex-
pression of ETS-2 on chromosome 21 in DS patients may con-
tribute to the increased rate of early senescence in circulating
lymphocytes. This together with decreased antiapoptotic pro-
tein Bcl-2 promotes apoptosis, which consequently contributes
to the abnormalities of the immune system observed in DS
patients.
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